BR9507811B1 - polipeptìdeos e composição farmacêutica. - Google Patents

polipeptìdeos e composição farmacêutica.

Info

Publication number
BR9507811B1
BR9507811B1 BRPI9507811-8A BR9507811A BR9507811B1 BR 9507811 B1 BR9507811 B1 BR 9507811B1 BR 9507811 A BR9507811 A BR 9507811A BR 9507811 B1 BR9507811 B1 BR 9507811B1
Authority
BR
Brazil
Prior art keywords
pct
image
polypeptides
phe
sec
Prior art date
Application number
BRPI9507811-8A
Other languages
English (en)
Other versions
BR9507811A (pt
Inventor
Klaus P Schaefer
Klaus Melchers
Ruediger Nave
Wolf-Ruediger Ulrich
Ernst Sturm
Uwe Krueger
Dietrich Haefner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6519392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9507811(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9507811A publication Critical patent/BR9507811A/pt
Publication of BR9507811B1 publication Critical patent/BR9507811B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BRPI9507811-8A 1994-05-31 1995-05-27 polipeptìdeos e composição farmacêutica. BR9507811B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4418936A DE4418936A1 (de) 1994-05-31 1994-05-31 Polypeptid
PCT/EP1995/002028 WO1995032992A1 (de) 1994-05-31 1995-05-27 Synthetische peptidanaloge des lungenoberflächenproteins sp-c

Publications (2)

Publication Number Publication Date
BR9507811A BR9507811A (pt) 1997-09-16
BR9507811B1 true BR9507811B1 (pt) 2009-05-05

Family

ID=6519392

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9507811-8A BR9507811B1 (pt) 1994-05-31 1995-05-27 polipeptìdeos e composição farmacêutica.

Country Status (29)

Country Link
US (1) US5874406A (pt)
EP (1) EP0764172B1 (pt)
JP (1) JP3359638B2 (pt)
KR (1) KR100355626B1 (pt)
CN (1) CN1130374C (pt)
AT (1) ATE275154T1 (pt)
AU (1) AU690280B2 (pt)
BG (1) BG63210B1 (pt)
BR (1) BR9507811B1 (pt)
CA (1) CA2191344C (pt)
CY (1) CY2552B1 (pt)
CZ (1) CZ286976B6 (pt)
DE (2) DE4418936A1 (pt)
DK (1) DK0764172T3 (pt)
EE (1) EE03775B1 (pt)
ES (1) ES2227548T3 (pt)
FI (1) FI118126B (pt)
HK (1) HK1000891A1 (pt)
HU (1) HU220191B (pt)
NO (1) NO317149B1 (pt)
NZ (1) NZ287447A (pt)
PL (1) PL181234B1 (pt)
PT (1) PT764172E (pt)
RO (1) RO118752B1 (pt)
RU (1) RU2145611C1 (pt)
SI (1) SI0764172T1 (pt)
SK (1) SK282441B6 (pt)
UA (1) UA35636C2 (pt)
WO (1) WO1995032992A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035882A1 (en) * 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
DE19851119C2 (de) 1998-11-06 2001-05-31 Byk Gulden Lomberg Chem Fab Behälter und Vorrichtung zur Blindung der Verabreichung von nicht festen pharmazeutischen Darreichungsformen bei der klinischen Prüfung
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
AU5400000A (en) * 1999-06-11 2001-01-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
EP1192184B1 (en) * 1999-06-17 2007-01-03 ALTANA Pharma AG Surfactant protein c esters
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU2003201A (en) * 1999-12-01 2001-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel use of lung surfactant
EP1259222A1 (en) * 2000-02-11 2002-11-27 ALTANA Pharma AG Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
US6660833B1 (en) 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
WO2001076619A1 (en) * 2000-04-12 2001-10-18 Altana Pharma Ag Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
AU2002338882B2 (en) 2001-10-11 2008-04-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel use of pulmonary surfactant
US6998384B2 (en) 2001-12-12 2006-02-14 The Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
CA2575513C (en) 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
AU2006203978B2 (en) 2005-01-06 2011-11-03 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
DE102005014650B3 (de) * 2005-03-31 2006-08-17 Altana Pharma Ag Anordnung aus Katheter und Anschlussstück sowie Ventil zum Durchführen eines Katheters
DE102005016229B3 (de) 2005-04-08 2006-06-14 Altana Pharma Ag Trockenvernebler
JP2010503731A (ja) * 2006-09-19 2010-02-04 ディスカバリー ラボラトリーズ，インコーポレイテッド 肺サーファクタント製剤および粘液クリアランスの促進方法
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
US8048043B2 (en) 2007-06-08 2011-11-01 Chiesi Farmaceutici S. P. A. Method of administration of a pulmonary surfactant
EP2370068A4 (en) 2008-12-10 2015-09-23 Paka Pulmonary Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
KR101767693B1 (ko) 2009-09-08 2017-08-23 키에시 파르마슈티시 엣스. 피. 에이. 폐 계면 활성제와 항산화 효소를 포함하는 치료용 혼합물
KR101957530B1 (ko) * 2010-08-23 2019-03-12 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 치료학적 활성 물질을 포함하는 가습 입자
EP3459556A1 (en) * 2012-02-09 2019-03-27 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Synthetic analogs of lung surfactant protein sp-c and their use
US20130303726A1 (en) * 2012-04-17 2013-11-14 Chiesi Farmaceutici S.P.A. Method for the preparation of surfactant peptides
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
RU2687776C2 (ru) 2014-03-05 2019-05-16 Фраунхофер-Гезельшафт Цур Фордерунг Дер Ангевандтен Форшунг Е.В. Увлажнитель для увлажнения аэрозоля
WO2016170087A1 (en) 2015-04-22 2016-10-27 Chiesi Farmaceutici S.P.A Method and system for effective breath-synchronized delivery of medicament to the lungs
EP3106090A1 (en) 2015-06-15 2016-12-21 CHIESI FARMACEUTICI S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
WO2016173634A1 (en) 2015-04-28 2016-11-03 Chiesi Farmaceutici S.P.A Device for facilitating the administration of a medicament to the lung by a catheter
JP2018514545A (ja) * 2015-04-30 2018-06-07 ユニバーシティ オブ ブレーメン 医療用および美容用の新規な皮膚ケア製造物
CA3028551A1 (en) 2016-07-28 2018-02-01 Chiesi Farmaceutici S.P.A. Method and system for delivery of an aerosolized medicament
RU2019114913A (ru) 2016-10-26 2020-11-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Устройство для облегчения введения лекарственного препарата в легкое с помощью катетера
CN110099695B (zh) 2016-12-22 2022-01-25 奇斯药制品公司 用于治疗进展性bpd的包含肺表面活性物质和类固醇的治疗组合
CN107163148A (zh) * 2017-05-15 2017-09-15 重庆理工大学 肺表面活性蛋白b前肽的重组蛋白及其制备方法和应用
TW201927286A (zh) 2017-12-15 2019-07-16 義大利商凱西製藥公司 用於噴霧投藥之包含肺表面張力素的藥學調配物
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
MX2020011127A (es) 2018-04-23 2021-01-15 Chiesi Farm Spa Combinacion terapeutica que comprende agente tensioactivo pulmonar y esteroide para la profilaxis de displasia broncopulmonar (bpd).
CN109001466A (zh) * 2018-07-19 2018-12-14 新疆维吾尔自治区人民医院 一种用于osa的肺表面活性蛋白试剂盒及其应用
EP3666316A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3666315A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3843105A1 (en) 2019-12-23 2021-06-30 PARI Pharma GmbH Control device for aerosol nebulizer system
WO2021151853A1 (en) 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59164724A (ja) * 1983-03-10 1984-09-17 Tokyo Tanabe Co Ltd サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
US5169761A (en) * 1984-12-11 1992-12-08 California Biotechnology Inc. Dna encoding and expression systems for alveolar surfactant proteins
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US5104853A (en) * 1984-12-11 1992-04-14 California Biotechnology Inc. Alveolar surfactant proteins having cys to ser mutations
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
WO1989004326A1 (en) * 1987-11-04 1989-05-18 California Biotechnology Inc. Alveolar surfactant proteins
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
DE3921954A1 (de) * 1989-07-04 1991-01-17 Thomae Gmbh Dr K Niedrig-viskose, hochkonzentrierte surfactant-suspension
JPH05294996A (ja) * 1992-04-17 1993-11-09 Tokyo Tanabe Co Ltd 合成ペプチド、それを含有する肺サーファクタント及び呼吸窮迫症候群治療剤

Also Published As

Publication number Publication date
NO965052D0 (no) 1996-11-27
AU690280B2 (en) 1998-04-23
ES2227548T3 (es) 2005-04-01
JPH10504025A (ja) 1998-04-14
FI964766A (fi) 1996-11-29
FI118126B (fi) 2007-07-13
RU2145611C1 (ru) 2000-02-20
BG63210B1 (bg) 2001-06-29
NO317149B1 (no) 2004-08-30
KR970703367A (ko) 1997-07-03
SK282441B6 (sk) 2002-02-05
PT764172E (pt) 2005-01-31
CZ350296A3 (en) 1997-05-14
HUT76952A (hu) 1998-01-28
HU220191B (hu) 2001-11-28
DE4418936A1 (de) 1996-02-08
FI964766A0 (fi) 1996-11-29
UA35636C2 (uk) 2001-04-16
MX9605986A (es) 1998-06-30
PL317420A1 (en) 1997-04-14
DK0764172T3 (da) 2005-01-10
HU9603249D0 (en) 1997-01-28
WO1995032992A1 (de) 1995-12-07
CN1154117A (zh) 1997-07-09
DE59510941D1 (de) 2004-10-07
CY2552B1 (en) 2008-07-02
PL181234B1 (pl) 2001-06-29
US5874406A (en) 1999-02-23
CN1130374C (zh) 2003-12-10
BR9507811A (pt) 1997-09-16
NZ287447A (en) 1998-01-26
SK152496A3 (en) 1997-06-04
ATE275154T1 (de) 2004-09-15
CA2191344C (en) 2003-04-08
CZ286976B6 (en) 2000-08-16
EE03775B1 (et) 2002-06-17
RO118752B1 (ro) 2003-10-30
EE9600175A (et) 1997-06-16
BG101028A (en) 1998-01-30
SI0764172T1 (en) 2005-02-28
KR100355626B1 (ko) 2002-12-26
EP0764172A1 (de) 1997-03-26
JP3359638B2 (ja) 2002-12-24
CA2191344A1 (en) 1995-12-07
AU2616995A (en) 1995-12-21
HK1000891A1 (en) 2004-09-17
EP0764172B1 (de) 2004-09-01
NO965052L (no) 1997-01-28

Similar Documents

Publication Publication Date Title
BR9507811B1 (pt) polipeptìdeos e composição farmacêutica.
DE69028671D1 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
NO963639D0 (no) Sublingual eller buckal farmasöytisk blanding
GB2282140A (en) Purified forms of DNAse
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DK193887A (da) Peptid med bronchodilartorisk og hypotensiv aktivitet
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
GR3006091T3 (pt)
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
ZA9510295B (en) Novel dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals
EP0291269A3 (en) Anti-tumour sulfonyl urea derivatives
FI971427A0 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
DK344489D0 (da) Substituerede 2-imidazoliner og fremstilling og anvendelse deraf
JPS649938A (en) Oral ingestive composition
AU7052191A (en) Antitumoral composition based on polypeptides having human interleukin 2 activity
CA2004764A1 (en) Ancrod proteins, their preparation and use
AU2065488A (en) The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O REQUERENTE DEVERA COMPLEMENTAR A TAXA RELATIVA A 1 REVINDICACAO EXEDENTE. O PEDIDO DE EXAME ( FOLHA 52 ) REFERE-SE A 11 REVINDICACOES, POREM O REQUERENTE DEPOSITOU 12 REVINDICACOES ( FOLHAS 136 E138 ).

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061558/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO0132272-32.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: NYCOMED GMBH, OKLAHOMA STATE UNIVERSITY, REGESTS OF THE UNIVERSITY OF MINNESOTA, OTSUKA PHARMACEUTICAL CO LTD, PLASMASEAL CORPORATION

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130004420, DE 14/10/2013

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 20130064421, APRESENTADA EM 23/07/2013, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA EM VIRTUDE DA EXTINCAO DA PATENTE PUBLICADA NA RPI NO 2241, DE 17/12/2013.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061558/2013-85 13A VARA FEDERAL DO RIO DE JANEIRO ORDINARIA / PROPRIEDADE INDUSTRIAL PROCESSO : 0132272-32.2013.4.02.5101 (2013.51.01.132272-3) AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI REU: REGENTS OF THE UNIVERSITY OF MINNESOTA, OKLAHOMA STATE UNIVERSITY, OTSUKA PHARMACEUTICAL CO. LTD., PLASMASEAL CORPORATION E NYCOMED GMBH. DECISAO: HOMOLOGO, POR SENTENCA, PARA QUE SE PRODUZA OS SEUS JURIDICOS E LEGAIS EFEITOS, OS ACORDOS FIRMADOS ENTRE O INPI E AS RES, CONFORME FLS. 87/89, 93/96, 138/139, 192/193 E 245, JULGANDO EXTINTO O PROCESSO, COM RESOLUCAO DO MERITO, NOS MOLDES DO ARTIGO 269, III DO CODIGO DO PROCESSO CIVIL, EM RELACAO AS ALUDIDAS EMPRESAS RES E AO

B25E Requested change of name of applicant rejected

Owner name: NYCOMED GMBH (DE)